-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $56

Benzinga·10/08/2026 14:54:08
Diffusion vocale
RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and lowers the price target from $58 to $56.